Drug Markets/Ceftazidime

Ceftazidime

5 NDCs across 3 manufacturers|5 Generic,0 Brand

Ceftazidime is used to treat acinetobacter infections, infectious bone diseases, escherichia coli infections, fever, haemophilus infections and klebsiella infections, per the National Library of Medicine's MED-RT classification.

▸ More about this market

The brand product was first FDA-approved on Jul 19, 1985, and the first generic was approved Nov 20, 1985. In 2024, Medicare Part D spent $2 million on Ceftazidime across 16,000 claims for 5,875 beneficiaries.

Ceftazidime is available as 5 NDCs from 3 manufacturers (5 generic, 0 brand), with NADAC prices from $3.70 to $9.51 per EAthe most expensive product costs about 2.6× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.

Total NDCs

5

5G / 0B

Manufacturers

3

competing in market

Price Spread

$3.70 – $9.51

per EA

7d Activity

5 flat

avg +0.0% WoW · of 5 NDCs

Market Price Trend

Monthly average NADAC per unit, split by generic and brand.

Drug Portfolio

5 NDCs total, 5 shown

Frequently Asked Questions

What is Ceftazidime used to treat?

Ceftazidime is used to treat acinetobacter infections, infectious bone diseases, escherichia coli infections, fever, haemophilus infections and klebsiella infections, per the National Library of Medicine's MED-RT classification.

When did Ceftazidime become available as a generic?

FDA approved the first generic Ceftazidime (ANDA) on Nov 20, 1985.

How much does Medicare spend on Ceftazidime?

In 2024, Medicare Part D spent $2 million on Ceftazidime across 16,000 claims for 5,875 beneficiaries.

How many Ceftazidime products are on the market?

The Ceftazidime drug market contains 5 NDCs from 3 manufacturers — 5 generic and 0 brand products.

What is the price range for Ceftazidime?

NADAC reference prices for Ceftazidime range from $3.7045 to $9.5080 per EA — the most expensive product costs about 2.6× the cheapest.

Which manufacturers make Ceftazidime?

3 manufacturers list Ceftazidime in NADAC. Ranked by number of NDCs, the largest are Hospira Inc. (2), Sagent Pharmaceuticals (2), WG Critical Care, LLC (1).